Literature DB >> 3875569

Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells.

S Ferrini, R Biassoni, A Moretta, M Bruzzone, A Nicolin, L Moretta.   

Abstract

T lymphocytes isolated from ascitic fluid of patients with stage III-IV ovarian carcinoma were cloned by means of a microculture system that allows cloning of virtually all peripheral blood human T lymphocytes. Under these experimental conditions, 15% to 42% of ascitic T cells gave rise to clonal progenies that were analyzed for different functional capabilities. Of the clones obtained, 36%-70% had cytolytic activity in a PHA-dependent assay (using P815 as target cells) that allowed detection of cytolytic cells of any specificity. About one-half of the cytolytic clones lysed the NK-sensitive K562 target cells as well. In addition, 30%-50% of the total clones released IL-2 upon stimulation with PHA for 24 hr. In all patients analyzed a variable proportion (11%-56% of all cytolytic clones) had cytolytic activity against autologous tumor cells. Some of these clones have been analyzed in more detail: 18/21 expressed the T4-T8+ phenotype, whereas the remaining 3 were T4+ T8-. Only one out of 6 clones tested lysed allogeneic ovarian carcinoma cells as well, while 5/8 had a definite NK-like activity. Finally, all 8 clones tested were inhibited by anti-T11 and 7/8 by anti-T8 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875569

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas.

Authors:  T L Whiteside; S Miescher; J Hurlimann; L Moretta; V von Fliedner
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.

Authors:  Isabelle Renard; Delia Mezzanzanica; Silvana Canevari; Silvano Ferrini; Jacques Boniver; Philippe Delvenne; Nathalie Jacobs
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2.

Authors:  R K Puri; D S Finbloom; P Leland; H Mostowski; J P Siegel
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

5.  Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

8.  Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.

Authors:  A Gorter; K M Krüse; P I Schrier; G J Fleuren; R J van de Griend
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

9.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

10.  Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.

Authors:  T L Knisely; J Y Niederkorn
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.